Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer
NCT05787561Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avutometinib and defactinib in Mesonephric adenocarcinoma (MNAC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response at 2 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
Mesonephric adenocarcinoma (MNAC)
Beyond the preview
Go deeper on NCT05787561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787561.